E2
Coproduction of emerging biomedical technologies

Convenors:
Ellen Moors (Copernicus Institute of Sustainable Development)
Wouter Boon (Utrecht University)
Thomas Reiss (Fraunhofer Institute for Systems and Innovation Research)
Michael Hopkins (University of Sussex)
Format:
Location:
C. Humanisticum AB 2.11
Start time:
17 September, 2014 at 14:00
Session slots:
3

Short abstract:

Long abstract:

In the current plans for Horizon 2020 healthcare and life sciences is defined as one of the grand societal challenges. These challenges become even more prominent when focussing on emerging and/or enabling health technologies and biomedical interventions, which are associated with a high degree of uncertainty, flexibility, and complexity. In this track we want to focus on co-production and coordination of developments in the field of emerging biomedical technologies. Emerging developments and platform technologies in the field of genomics, synthetic biology, diagnostics, nanotechnology and neuroscience, for example, demand coordination in flexible and responsive ways. There is wide array of possible socio-technological innovation related topics to be addressed, making several cross-sections, e.g. ranging from early stage to late stage issues in the health innovation process, and focussing on various actors situated in the health and care field, ranging from academic researchers and regulatory agencies to hospitals, industry , patient organizations and citizens communities. This track invites contributions to the following themes: -Responsible innovation of emerging biomedical technologies; -Role of users and user communities; -Regulation of 'big data' in emerging biomedical technologies; -Convergence of technologies, disciplines and sectors (e.g. personalized medicine, theranostics, cognitive human-enhancement technologies, recreative drugs, healthy food, and nano-enabled drug delivery systems), and related science, technology and innovation policies; -Transition to new business and governance models for the coordination of emerging biomedical technologies (e.g. open/open-source innovation, self-regulation, soft regulation, fast and conditional approvals, new role of IPR and standards/norms). The papers will be presented in the order shown and grouped 3-4-3 between sessions